Maria Teresa Petrucci

Summary

Affiliation: University of Rome La Sapienza
Country: Italy

Publications

  1. ncbi A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma
    Maria T Petrucci
    Department of Cellular Biotechnology and Haematology, Sapienza University of Rome, Rome, Italy
    Br J Haematol 160:649-59. 2013
  2. ncbi Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study
    Maria Teresa Petrucci
    Hematology Service, Department of Cellular Biotechnology and Hematology, Sapienza University, Rome, Italy
    Cancer 119:971-7. 2013
  3. doi Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3
    Cinzia Fionda
    Department of Molecular Medicine, Cenci Bolognetti Foundation Pasteur Institute, Sapienza University of Rome, 00161 Rome, Italy
    J Immunol 190:6662-72. 2013
  4. pmc IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy
    Francesco Pisani
    Department of Hematology, Regina Elena National Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 31:17. 2012
  5. ncbi Reactive Oxygen Species- and DNA Damage Response-Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1
    Alessandra Soriani
    Department of Molecular Medicine, Pasteur Institute Cenci Bolognetti Foundation, Sapienza University of Rome, 00161 Rome, Italy
    J Immunol 193:950-60. 2014
  6. ncbi Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis
    Ombretta Annibali
    Dipartimento di Ematologia, Università Campus Bio Medico, Rome, Italy
    Cancer 103:582-7. 2005
  7. doi Relapse of IgA lambda multiple myeloma presenting as obstructive jaundice and abdominal pain
    Ombretta Annibali
    Hematology, University Campus Bio Medico, Rome, Italy
    Onkologie 32:119-21. 2009
  8. doi Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form
    Angela Rago
    Department of Cellular Biotechnologies and Hematology, Sapienza University Polo Pontino, Rome, Italy
    Cancer 118:5544-9. 2012
  9. ncbi Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients
    Tommaso Za
    Institute of Haematology, Catholic University, Rome, Italy
    Br J Haematol 160:673-9. 2013
  10. ncbi Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma
    Claudio Cartoni
    Hematology, Department of Haematology, Oncology, Pathology and Regenerative Medicine, Policlinico Umberto I, Sapienza University Rome, Rome, Italy
    Support Care Cancer 20:2621-6. 2012

Collaborators

Detail Information

Publications15

  1. ncbi A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma
    Maria T Petrucci
    Department of Cellular Biotechnology and Haematology, Sapienza University of Rome, Rome, Italy
    Br J Haematol 160:649-59. 2013
    ..5 and 8.9 months, respectively. In conclusion, bortezomib retreatment was effective and tolerable in relapsed MM patients, with no evidence of cumulative toxicities...
  2. ncbi Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study
    Maria Teresa Petrucci
    Hematology Service, Department of Cellular Biotechnology and Hematology, Sapienza University, Rome, Italy
    Cancer 119:971-7. 2013
    ..In elderly patients with newly diagnosed multiple myeloma (MM), the addition of bortezomib to standard, combined oral melphalan and prednisone (MP) significantly increases the response rate and event-free survival compared with MP alone...
  3. doi Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3
    Cinzia Fionda
    Department of Molecular Medicine, Cenci Bolognetti Foundation Pasteur Institute, Sapienza University of Rome, 00161 Rome, Italy
    J Immunol 190:6662-72. 2013
    ..Thus, we provide evidence that regulation of the NKG2D-ligand MICA expression may represent an additional immune-mediated mechanism supporting the antimyeloma activity of GSK3 inhibitors...
  4. pmc IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy
    Francesco Pisani
    Department of Hematology, Regina Elena National Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 31:17. 2012
    ..Immunoglobulin D multiple myeloma (MM) is rare and has a poorer prognosis than other MM isotypes...
  5. ncbi Reactive Oxygen Species- and DNA Damage Response-Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1
    Alessandra Soriani
    Department of Molecular Medicine, Pasteur Institute Cenci Bolognetti Foundation, Sapienza University of Rome, 00161 Rome, Italy
    J Immunol 193:950-60. 2014
    ..We propose immunogenic senescence as a mechanism that promotes the clearance of drug-treated tumor cells by innate effector lymphocytes, including NK cells. ..
  6. ncbi Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis
    Ombretta Annibali
    Dipartimento di Ematologia, Università Campus Bio Medico, Rome, Italy
    Cancer 103:582-7. 2005
    ....
  7. doi Relapse of IgA lambda multiple myeloma presenting as obstructive jaundice and abdominal pain
    Ombretta Annibali
    Hematology, University Campus Bio Medico, Rome, Italy
    Onkologie 32:119-21. 2009
    ..Only few cases of pancreatic involvement of multiple myeloma (MM) have been reported in the medical literature...
  8. doi Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form
    Angela Rago
    Department of Cellular Biotechnologies and Hematology, Sapienza University Polo Pontino, Rome, Italy
    Cancer 118:5544-9. 2012
    ..In 144 patients with SMM, we also compared the risk of progression predicted by bone marrow plasma cell (BMPC) involvement on the bone marrow biopsy (BMB) versus bone marrow aspirates (BMA)...
  9. ncbi Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients
    Tommaso Za
    Institute of Haematology, Catholic University, Rome, Italy
    Br J Haematol 160:673-9. 2013
    ..Finally, the risk of venous thrombosis did increase when the M-protein concentration exceeded >16 g/l...
  10. ncbi Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma
    Claudio Cartoni
    Hematology, Department of Haematology, Oncology, Pathology and Regenerative Medicine, Policlinico Umberto I, Sapienza University Rome, Rome, Italy
    Support Care Cancer 20:2621-6. 2012
    ..This study assessed the effectiveness of controlled-release (CR) oral oxycodone in controlling pain and its interference on daily functions of patients with hematologic malignancies affected by BIPN...
  11. doi ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
    Alessandra Soriani
    Department of Experimental Medicine, Istituto Pasteur Fondazione Cenci Bolognetti, Rome, Italy
    Blood 113:3503-11. 2009
    ....
  12. ncbi High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: comparison with a historical control
    Saveria Capria
    Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Rome, Italy
    Acta Haematol 115:9-14. 2006
    ....
  13. ncbi Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease
    Alessandro Pulsoni
    Department of Cellular Biotechnology and Hematology, La Sapienza University, Rome, Italy
    Drugs Aging 19:947-53. 2002
    ..For these patients we retrospectively evaluated the effect of a mild approach with continuous low-dose melphalan and prednisone (cMP)...
  14. doi Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies
    Maria Rosaria Ricciardi
    Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Via Benevento 6, 00161, Rome, Italy
    J Mol Med (Berl) 90:1133-44. 2012
    ..Deeper understanding of the molecular mechanisms of action of MEK inhibitors will likely translate into more effective targeted strategies for the treatment of AML...
  15. doi Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy
    Federica Moschella
    Department of Hematology Oncology and Molecular Medicine, Istituto Superiore di Sanita, Viale Regina Elena 299, Rome 00161, Italy
    Clin Cancer Res 19:4249-61. 2013
    ..A better understanding of the cellular and molecular basis of cyclophosphamide-mediated immunomodulation is needed to improve the efficacy of chemoimmunotherapy...